HOUSTON, TX - April 29, 2025 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR) is excited to announce continued significant growth of its wholly owned subsidiary, Neutra Life Sciences. Since the successful launch of its Site Management Organization (SMO), Neutra Life Sciences has rapidly expanded its footprint by securing multiple Joint Venture Partnerships with private practices, opening four new clinical research sites across diverse specialties.
These newly launched sites include:
- Urgent Care, Family Medicine & IV Therapy
- NeuMed Urgent Care & IV Therapy (www.neumed.com)
- Optometry
- Nanda Dry Eye & Vision Institute (www.docnanda.com)
- Interventional Cardiology
- Apex Cardiology of Houston (www.apexhouston.com)
- Pediatric Pulmonology
- Texas Lung & Sleep Associates (www.txlungandsleep.com)
These expansions mark a major step forward in Neutra Life Sciences’ commitment to delivering high-quality, integrated clinical research services. The company’s growing network strengthens its multispecialty capabilities, allowing it to serve a broader patient population and meet increasing demands in clinical research.
Neutra Life Sciences plans to expand into additional specialties, further enhancing its ability to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. This strategic growth enables the company to play a critical role in accelerating the development of innovative treatments across a broader spectrum of therapeutic areas.
“Our growth reflects the increasing demand for high-quality, integrated clinical research solutions,” said Sydney Jim, President and CEO of Neutra Corp. “By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research.”
Neutra Life Sciences remains focused on building a robust network of clinical research sites, delivering exceptional service to its partners, and advancing its mission to improve health outcomes through cutting-edge collaboration.
For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, don't hesitate to contact Neutra Life Sciences via phone 281-598-0200 or email at info@neutralifesciences.com.
Earlier this quarter, Neutra Corp. inked a Letter of Intent to acquire www.curaconnector.com, a healthcare technology and digital company owning a patent-pending technology platform that streamlines how outpatient care is delivered and supplied. Curaconnector updates are coming in the upcoming months.
About Neutra Corp
Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.
Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.
Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
View the original release on www.newmediawire.com
